News | September 27, 2022
– atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers – EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative… Read More
Articles | June 17, 2022
NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June: BIO International Conference Format: Company Presentation – In Person… Read More
News | May 16, 2022
– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of… Read More
Articles | May 4, 2022
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai… Read More
Articles | January 26, 2021
atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital and its new initiative, the Center for Neuroscience of Psychedelics, to advance novel… Read More
Articles | January 12, 2021
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has acquired a majority stake in Recognify Life Sciences, an entity developing a treatment for Cognitive Impairment associated with Schizophrenia (CIAS). Recognify’s lead compound, “RL-007”,… Read More
Articles | December 16, 2020
atai Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financial Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Medical Officer (CMO). Read More
Articles | November 23, 2020
ATAI Life Sciences, a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $125 million Series C financing round, including $32 million of its 2020 convertible debt that converted in connection with the Series C. Read More
Mission | November 16, 2020
Substance Use Disorders (SUDs) and related disorders are a significant source of morbidity and mortality and pose a substantial cost to society Over 20m people live with a SUD in the U.S., and since the drug epidemic started in 1999, there have been over 900,000 overdose fatalities. For an already vulnerable population, COVID-19 severely exacerbated… Read More
Mission | November 16, 2020
Anxiety is considered a common aspect of life, however anxiety disorders develop when feelings of apprehension and unease persist over an extended period and potentially worsen over time. Anxiety disorders, which are believed to stem from a set of risk factors including genetics, neurochemistry, life experiences and personality, can have… Read More